Vera: TRUTAKNA stabilizes eGFR, cuts kidney-progression risk 76% in ORIGIN 3 final analysis
Vera announced TRUTAKNA met all prespecified endpoints in ORIGIN 3, stabilizing eGFR and reducing kidney—disease progression risk by 76%.Key Highlights:Original SEC Filing: Vera Therapeutics, Inc. [ VERA ] - 8-K - Sep. 15, 2026This is an AI-powered summary. It may contain inaccuracies. Consider ver…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.